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Abstract
A critical question in tuberculosis control is why some strains of Mycobacterium tuberculosis are 
preferentially associated with multiple drug resistances. We demonstrate that M. tuberculosis 
strains from Lineage 2 (East Asian lineage and Beijing sublineage) acquire drug resistances in 
vitro more rapidly than M. tuberculosis strains from Lineage 4 (Euro-American lineage) and that 
this higher rate can be attributed to a higher mutation rate. Moreover, the in vitro mutation rate 
correlates well with the bacterial mutation rate in humans as determined by whole genome 
sequencing of clinical isolates. Finally, using a stochastic mathematical model, we demonstrate 
that the observed differences in mutation rate predict a substantially higher probability that 
patients infected with a drug susceptible Lineage 2 strain will harbor multidrug resistant bacteria 
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at the time of diagnosis. These data suggest that interventions to prevent the emergence of drug 
resistant tuberculosis should target bacterial as well as treatment-related risk factors.
Recently, strains of Mycobacterium tuberculosis have emerged that are resistant to most or 
all effective antibiotics1-4. Given the low mutation rate of M. tuberculosis5,6 and its slow 
replication rate, it is unclear how the bacterium acquires resistance to multiple antibiotics, 
especially in the face of concurrent multiple drug treatment. The most commonly cited risk 
factors for treatment failure due to antibiotic resistance are patient noncompliance1-4,7-9, 
inappropriate drug regimens and dosing2,5,6,9,10 and primary infection with drug resistant 
strains11,12. The relative importance of bacterial determinants of treatment failure has been 
unclear. Recently, whole genome sequencing of M. tuberculosis isolates has revealed the 
importance of novel mutation in the emergence of drug resistance13-15. Sequencing of M. 
tuberculosis from patients failing antibiotic therapy revealed that new antibiotic resistance 
mutations can arise multiple times within a given individual15. Moreover, several studies 
suggest that certain strains of M. tuberculosis may be more frequently associated with multi-
drug resistance (MDR) 16,17. Given that all drug resistances in M. tuberculosis occur 
through chromosomal mutation, these data suggest that the mutational capacity of the 
bacterium may be an important determinant of the likelihood of drug resistance.
M. tuberculosis forms phylogeographic lineages associated with particular human 
populations18-21. Though less genetically diverse than many other pathogens, there is both 
experimental and clinical evidence that M. tuberculosis strains from different lineages vary 
in their capacity to cause disease20-24 and acquire drug resistance11,12,16,20,25-28. 
Specifically, M. tuberculosis strains within Lineage 2 (the East Asian lineage, which 
includes the Beijing family of strains) have been epidemiologically associated with an 
increased risk of drug resistance in several cross-sectional studies in diverse locales, though 
not in all29. Strains from this lineage have polymorphisms in DNA replication, 
recombination, and repair genes as compared to Lineage 4 (the Euro-American lineage) 
strains, raising the possibility that they are more mutable than other M. tuberculosis 
strains30. However, these epidemiologic observations might also reflect social and 
programmatic factors (such as noncompliance and inappropriate dosing) correlating with the 
phylogeography of the Lineage 2 strains. Indeed, in vitro studies comparing the rate or 
frequency of drug resistance in the Lineage 2 and Lineage 4 strains have produced differing 
results31,32. Here, we sought to determine the rate at which M. tuberculosis strains of 
different lineages acquire drug resistance and the effect of strain based differences in 
mutation rate on the predicted de novo generation of MDR in patients with tuberculosis.
Results
Effect of mutation and genetic background on drug resistance in M. tuberculosis
To measure the drug resistance rate of strains from different M. tuberculosis lineages, we 
performed Luria-Delbrück fluctuation analysis33,34 on a panel of laboratory and clinical 
isolates from both Lineage 2 and Lineage 4. All strains were fully drug susceptible, with 
MIC's at least 100 fold less than the drug concentrations at which we assessed drug 
resistance rates (MICrif<0.015μg/mL; MICINH<0.007 μg/mL, Supplemental Table 1). 
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Within both lineages, there was some strain-to-strain variation in the rate at which 
rifampicin resistance was acquired (Figure 1). However, every strain from Lineage 2 
acquired resistance to rifampicin (2μg/mL) at a significantly higher rate than every Lineage 
4 strain, with a nearly 10-fold difference between the means of the two groups (Figure 1, 
Supplementary Table 1).
The higher rate of rifampicin resistance could reflect three possible mechanisms: 1) 
differences in the ability to survive and mutate after exposure to antibiotic, 2) inherent 
differences in the number of rpoB mutations conferring rifampicin resistance (target size), or 
3) differences in the basal mutation rate in the absence of selection. To test these hypotheses, 
we chose well-characterized representatives from Lineage 4 and Lineage 2 - CDC1551 and 
HN878, respectively - for further study.
Differences in response to antibiotic
We first sought to determine whether Lineage 4 and Lineage 2 strains differed in their 
ability to acquire drug resistance after exposure to rifampicin. Fluctuation analysis assumes 
that all mutations occur prior to selection and that all mutants replicate as well as wild 
type33; however, if a strain is capable of surviving and mutating in the presence of drug, it 
will produce a greater number of drug-resistant mutants. Building on similar studies in 
Saccharomyces cerevisiae35, we reasoned that if mutations occur in the presence of a drug, 
then lowering the drug concentration might allow strains from both lineages to grow and 
acquire mutations post-exposure. Conversely, increasing the drug concentration might 
abrogate the ability of both strains to survive and acquire mutations in the presence of drug. 
However, we found that statistically significant increases in the rifampicin resistance rate for 
the Lineage 2 strain, HN878, relative to the Lineage 4 strain, CDC1551, were maintained 
over 10-fold variation in drug concentration (0.5μg/mL – 5μg/mL) (Figure 2, Supplementary 
Table 1).
To extend these findings, the distribution of mutations observed in each fluctuation assay 
can be analyzed using tools developed by Lang et al35. This analysis takes advantage of the 
fact that mutations occurring in culture, prior to antibiotic exposure, result in a Luria-
Delbrück distribution. While mutations arise according to a Poisson distribution, the 
subsequent outgrowth of mutants during broth culture generates a Luria-Delbrück 
distribution. In contrast, mutations occurring after plating on antibiotic will occur according 
to a Poisson distribution without the expansion in culture that creates a Luria-Delbrück 
distribution33,36,37. Thus, the appearance of any additional mutants resulting from 
acquisition of resistance after antibiotic exposure will generate a mixed distribution of the 
number of mutants, containing a Poisson-distributed number of post-plating mutants and a 
Luria-Delbrück-distributed number of mutants occurring prior to drug exposure.
We therefore used a curve-fitting approach to determine whether the distribution of mutant 
frequencies in the two strains is better fit using a one-parameter Luria-Delbrück model, or a 
two-parameter Luria-Delbrück and Poisson mixture model (Figure 3a-f). The algorithm first 
fits the data to a Luria-Delbrück model alone, and then optimizes the fit with the addition of 
a Poisson model. A purely Poisson model was also fit to serve as a reference. We used the 
Akaike information criterion with correction for sample size (AICC) to identify instances 
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where the Luria-Delbrück model alone provided the optimal fit over either the Poisson 
model or the two parameter mixture model38,39. The AICC quantifies the evidence in favor 
of using a more complex model (here, the two parameter mixture model) over a simpler 
(here, Luria-Delbrück) model, appropriately penalizing the fit of the more complex model 
by the increase in model complexity. As expected, the ΔAICc (AICC(Luria-Delbrück) - 
AICC(Poisson)) was highly negative in all conditions, confirming that the Luria-Delbrück 
model fits the distributions significantly better than the Poisson model alone (Supplementary 
Table 2). More revealing, the ΔAICc (AICC(Luria-Delbrück) - AICC(two parameter)) was 
also negative, indicating that there is insufficient evidence to support the inclusion of an 
additional Poisson component in the Luria-Delbrück distributions (Figure 3g, 
Supplementary Table 2). This suggests that post-exposure mutation is not responsible for the 
higher rifampicin resistance rate in HN878, the Lineage 2 (East Asian) strain.
This analytic approach also suggests that the difference in rifampicin resistance rates is not 
due to strain based differences in the fitness effects of the drug-resistance mutations33,37. If 
the drug resistant mutants in either strain suffered a strong fitness cost, the outgrowth of 
mutants in culture prior to selection would have been slower than drug susceptible cells, 
driving the Luria-Delbrück distribution back towards the underlying Poisson distribution of 
mutation. However, our data suggest that in both strains, drug-resistant mutants occur 
primarily according to a Luria-Delbrück distribution.
Differences in target size
Rifampicin resistance is encoded by multiple mutations in the rifampicin resistance-
determining region (RRDR) of rpoB. Strains in which there are a greater number of potential 
mutations in the RRDR that produce drug resistance would more rapidly acquire resistance 
to rifampicin. Therefore, we sought to determine whether M. tuberculosis strains of different 
lineages differ in the total number of mutations that confer rifampicin resistance, accounting 
for differences in the rifampicin resistance rates. We sequenced the RRDR of rpoB from 600 
independent mutants (100 from each fluctuation assay in Figure 2) to determine the number 
of mutations conferring rifampicin resistance in both strains under each condition tested 
above (Figure 4a, Supplementary Table 3). Though there is potentially a discrepancy 
between drug resistance mutants found in vitro and in vivo40, all of the mutations that we 
identified correspond to mutations seen clinically41. For both strains, the target size became 
smaller as drug concentration increased, indicating that some rpoB mutations generate lower 
level rifampicin resistance. There were small differences in target size between the two 
strains at two of the three drug concentrations tested, such that the number of mutations 
conferring resistance at both 0.5 and 2μg/mL was higher in the Lineage 2 strain. These data 
suggest that target size differences between strains contribute to strain based differences in 
the acquisition of rifampicin resistance. However, correcting for target size to determine the 
per base pair mutation rate, the Lineage 2 strain, HN878, remained significantly higher than 
the Lineage 4 strain, CDC1551, at each of the drug concentrations tested (Figure 4b, 
Supplementary Table 4). Therefore, it is likely differences in basal mutation rate that lead to 
differences in the acquisition of rifampicin resistance.
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Resistance to other antibiotics
If the mutation rate of HN878 is higher than that of CDC1551, then the Lineage 2 M. 
tuberculosis strain should also acquire resistances to other antibiotics at a higher rate. We 
therefore assessed the rate at which HN878 and CDC1551 acquire resistance to ethambutol 
(5μg/mL) and isoniazid (1μg/mL). For both antibiotics, the rate of resistance was nearly 3-
fold (2.51 and 2.75, respectively) higher in the Lineage 2 strain, HN878, consistent with the 
increased rate of rifampicin resistance (Figure 5, Supplementary Table 1). Taken together, 
these results suggest that M. tuberculosis strains from Lineage 2 have a higher basal 
mutation rate than strains from Lineage 4.
In vitro mutation rates to predict in vivo resistance
We then sought to understand how these in vitro measures of mutation translate to the in 
vivo environment. In our previous work, we determined that in nonhuman primates, M. 
tuberculosis mutates at a relatively fixed rate over time and this in vivo per-day mutation 
rate is well-approximated by the in vitro per-day mutation rate as measured by fluctuation 
analysis and adjusted for target size6. To determine if the in vitro mutation rate is similarly 
concordant with the mutation rate of M. tuberculosis during human infection, we analyzed 
the whole genome sequences of M. tuberculosis isolates derived from an outbreak of a 
Lineage 4 (Euro-American) strain in British Columbia, Canada42. We determined the 
number of SNPs in each strain relative to a historical isolate, identifying SNPs according to 
parameters that were experimentally validated through Sanger resequencing in our previous 
work (Figure 6a). By reconstructing the phylogeny of these strains through Bayesian 
Markov chain Monte Carlo analysis 43,44 (Supplementary Figure 1), and informing the 
phylogeny with dates for each isolate, we have estimated the base substitution rate 
(equivalent to the mutation rate under a neutral model of evolution45) in this outbreak. 
Strikingly, we found that the British Columbia strains acquired mutations at approximately 
the same rate over time as previously shown for M. tuberculosis strains isolated from 
macaques with active and latent disease irrespective of disease course (Figure 6b, 
Supplementary Table 5). In addition, the rate at which these strains acquired mutations in 
vivo was well approximated by the in vitro per-day mutation rate of the Lineage 4 strain 
(Erdman) used in the macaque infections as defined by fluctuation analysis. Finally, 
consistent with both our previous work6 and the work of others46, these data indicate that a 
molecular clock of 0.3-0.5 mutations/genome/year may be applicable to analysis of M. 
tuberculosis genetic diversity over the time scales assessed here.
A time-based model of mutation and drug-resistance predicts MDR before treatment
Given these data, we developed a stochastic simulation model of the evolution of drug 
resistance within a patient in order to assess the potential clinical impact of the observed 
differences in mutation rate between Lineage 2 and Lineage 4 strains. Our model of drug 
resistance utilizes a stochastic mutation parameter in which mutation occurs at a constant 
rate over time and we informed this parameter with the in vitro mutation rates for CDC1551 
and HN878 as a proxy for their mutation rates in the human host (Supplementary Figure 2a, 
Supplementary Table 6). We used this model to simulate the emergence of MDR (defined 
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here as resistance to both rifampicin and isoniazid) within an infected individual prior to 
diagnosis and treatment (Supplementary Figure 2b).
In the model, as a result of the differences in mutation rate, patients infected with the 
Lineage 2 strain, HN878, are at a significantly increased risk of MDR before treatment as 
compared to patients infected with the Lineage 4 strain, CDC1551 (Figure 7a). When all 
other parameters (birth, death, fitness and bacterial burden at the time of diagnosis) are kept 
equal, the difference in the probability of MDR before diagnosis and treatment is 
approximately 22-fold. We find similar results when using an alternative model of drug 
resistance developed by Colijn et al in which mutation is replication- rather than time-
dependent (Supplementary Figure 2c)47. We assessed the sensitivity of our model to 
fluctuations in both growth rate and fitness (Figure 7b & c). Varying these parameters does 
not alter our principle conclusion that patients infected with Lineage 2 strains of M. 
tuberculosis are at a significantly higher risk for the de novo acquisition of MDR, reflecting 
the multiplicative effects of an increased risk of acquiring each individual drug resistance 
due to a higher basal mutation rate.
Discussion
Here we demonstrate that strains from Lineage 2 of M. tuberculosis (the East Asian lineage, 
which includes the Beijing family of strains) acquire drug resistances in vitro more rapidly 
than strains from Lineage 4 (the Euro-American lineage). This is likely not the result of an 
enhanced ability of these strains to survive and mutate in the presence of drug, and we find 
no evidence of strong fitness effects that would explain the observed differences in drug 
resistance rates. Interestingly, we do find evidence that the genetic context of a given M. 
tuberculosis strain can impact the range of observed mutations conferring resistance to a 
single drug. In our analysis, the Lineage 2 strain, HN878, was permissive for a broader 
range of rpoB mutations than the Lineage 4 strain, CDC1551. However, the difference in 
target size is not sufficient to explain the observed difference in rifampicin resistance rates, 
suggesting that a basal difference in mutation before selection drives the accelerated rate of 
drug resistance in HN878. In support of this, we find that HN878 more rapidly acquires 
resistance to not only rifampicin, but also isoniazid and ethambutol.
We also find significant variation in the mutation rates of the other strains within each 
lineage. Previous analyses suggest that there is substantial genetic and phenotypic diversity 
among isolates from the various M. tuberculosis lineages48. We expect that differences in 
mutation rate and differences in target size both contribute to the two to thirty-five fold 
differences in rifampicin resistance rates that we have measured in these other strains. 
Further work will be required to establish the relative contribution of these factors to the 
drug resistance rate of each strain and to determine to what extent these findings can be 
generalized to strains from other M. tuberculosis lineages.
To establish the in vivo relevance of these findings, we sought to assess the concordance 
between mutation rates measured in vitro and in vivo. Strikingly, we found that the mutation 
rate of M. tuberculosis in vitro is very close to the mutation rate – assessed as mutation per 
unit time – in isolates from a human transmission chain. Thus, M. tuberculosis acquires 
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mutations at a similar rate over time in people as it does in an actively growing culture. This 
is consistent with our previous findings that the in vitro mutation rate over time was similar 
to the rate of mutation over time in M. tuberculosis isolated from macaques with latent and 
active disease. Taken together, these findings define a molecular clock for M. tuberculosis 
that may be used in future evolutionary and epidemiologic studies, though care must be 
taken to identify and compensate for potential sources of variation in rate49,50.
We propose two possible explanations for the finding that M. tuberculosis acquires 
mutations at the same rate over time in vitro, in macaques, and across a human transmission 
chain. First, there may be a population of M. tuberculosis replicating in vivo at a rate similar 
to the replication rate in vitro. These same bacteria may be over-represented in culturable 
clinical isolates, suggesting that they may be more likely to cause disease and be 
transmitted. Alternatively, it is possible that the mutation rate of M. tuberculosis is driven by 
a time dependent rather than a replication dependent factor. For example, the replicative 
error rate in M. tuberculosis could be very low relative to time and mutations may occur 
both in vitro and in vivo largely through DNA damage from endogenous metabolic 
processes or exogenous stressors.
We expect that these models may be resolved in part by elucidating the molecular basis of 
strain-based differences in mutation rate. The differences in mutation rate between clinical 
M. tuberculosis strains measured here are more modest than the differences that distinguish 
clinical isolates of other bacteria such as Pseudomonas aeruginosa or Escherichia coli51-53. 
Clinical isolates of these pathogens may become orders of magnitude more mutable than 
wild type strains through the loss of mismatch repair51. However, mycobacteria, like all 
other actinomycetes, lack mismatch repair entirely54,55, and the molecular basis of 
replicative fidelity in mycobacteria remains unclear. While mutations in DNA replication 
and repair genes are enriched in some M. tuberculosis strains from Lineage 230, no single 
point mutation has been found to accelerate the basal mutation rate of M. tuberculosis in 
isogenic strains. Importantly, Lineage 2 strains also differ in important metabolic pathways 
from Lineage 4 strains56,57. Thus, it is possible that genetic differences outside DNA 
replication and repair contribute to the differences in mutation rate that we have measured.
We have used the observation that M. tuberculosis mutates at a constant rate per unit time to 
develop a predictive model of the evolution of MDR in vivo. Our model demonstrates that it 
is possible to see multi-drug resistance evolve before the onset of treatment, consistent with 
a prior replication-dependent model47. Moreover, differences in mutation rate have 
approximately multiplicative effects for each mutation required, leading to stark differences 
in the de novo generation of MDR. Indeed, we parameterized our model with data from 
HN878, which has only modestly elevated acquisition rates of rifampicin and isoniazid 
resistance. Strain X005632 has a 35-fold higher rate of rifampicin resistance as compared to 
CDC1551. With a similarly elevated rate of isoniazid resistance, the risk of MDR in an 
individual infected with X005632 would be nearly three orders of magnitude higher than for 
a patient infected with CDC1551. The predicted differences in the occurrence of at least one 
MDR bacterium within infected patients may not be directly proportional to the clinical risk 
of drug resistant tuberculosis because individual bacteria may not have equal capacity to 
cause disease. However, the magnitude of these differences suggests that strain based 
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variation in drug resistance rates is an important risk factor for the development of drug 
resistant disease. Indeed, just as strains with higher mutation rates have increased risk of 
drug resistance mutations and mutations that facilitate acquisition of drug resistance (i.e. 
efflux pumps58-60), these strains have increased capacity to acquire compensatory 
mutations61 that may enhance their fitness in vivo.
While our model focused on the evolution of multidrug resistance (rifampicin and isoniazid 
resistance), the findings are applicable to the evolution of resistances to any antibiotic. New 
antibiotics and novel regimens of new and current antibiotics are being developed, 
combining drugs for which resistance is not yet prevalent. The expectation is that with 
proper implementation, a novel regimen will treat patients infected with MDR M. 
tuberculosis and prevent the emergence of resistance to new drugs62,63. However, both 
clinical and high resolution sequencing evidence suggests patients fail therapy with strains 
that are resistant to only a subset of antibiotics administered14,15,64. Thus, even in the 
context of a novel regimen, resistance to these new antibiotics may be difficult to avoid 
especially in the context of infection by strains from Lineage 2.
Consistent with epidemiologic data suggesting that severe disease at diagnosis is associated 
with the acquisition of MDR in new cases65,66, our model also predicts that bacterial burden 
is a critical determinant of the probability of drug resistance. In the face of substantial 
capacity for mutation and resistance, early and active case detection with novel, sensitive 
point of care diagnostics remains our best hope of curbing the drug resistance epidemic. 
Smear microscopy is the most common primary diagnostic for M. tuberculosis around the 
world but is orders of magnitude less sensitive than both culture and molecular 
diagnostics67,68. If, as our model suggests, higher bacterial burden at diagnosis results in 
increased risk for the evolution of MDR M. tuberculosis, then improving diagnostic 
sensitivity will not only curtail ongoing transmission of disease as previously suggested69,70, 
but also limit the de novo emergence of drug resistance. The risk of drug resistance appears 
to be even higher in the setting of infection with Lineage 2 strains of M. tuberculosis. Taken 
together, these data emphasize that M. tuberculosis strains differ in their propensity for 
acquiring drug resistance and suggest that these biological factors should be considered in 
efforts to limit the emergence of novel resistances to both existing antibiotics and new 
treatment regimens.
Methods
Culture and MIC determination of clinical isolates
Clinical Strains were identified as previously described71. Strains were grown in broth 
culture of 7H9 supplemented with 10% Middlebrook OADC, 0.0005% tween 80, and 
0.005% glycerol. To determine MIC, strains were grown to log phase (OD 0.5 to 0.8), and 
diluted to an OD of 0.006. Wells were inoculated with 50μL of culture and then 
supplemented with 50μL of media containing the appropriate concentration of drug. All 
concentrations were tested in triplicate, and two sets of triplicate control wells were 
established for each strain. After 6 days, 10μL of Alamar Blue (Life Technologies) was 
added to each well of one triplicate set of controls, where control wells were not 
supplemented with antibiotic. If control wells converted from blue to pink after 24 hours, 
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10μL of Alamar Blue was added to each triplicate set of experimental wells as well as a new 
set of control wells. All wells were examined after 24 hours. Any wells that remained blue 
represented inhibition of growth. The following concentrations were tested: 0.5, 0.25, 0.125, 
0.06125, 0.03063, 0.01531μg/mL of rifampicin (Sigma); 0.25, 0.125, 0.06125, 0.03063, 
0.01531, 0.00766μg/mL of isoniazid (Sigma). The MIC was defined as the lowest 
concentration of drug that prevented color change from blue to pink.
Fluctuation analysis
Fluctuation analysis was performed as previously described6. Briefly, for a single strain of 
M. tuberculosis, starter cultures were inoculated from freezer stocks of optical density (OD) 
1.0 culture. Once at an OD of 0.7 to 1.1, approximately 300,000 cells were used to inoculate 
120mL of Middlebrook 7H9 supplemented with 10% Middlebrook OADC, 0.0005% tween 
80, and 0.005% glycerol, giving a total cell count of 10,000 cells per 4mL culture. This 
volume was immediately divided to start 24 cultures of 4mL each in 30mL square PETG 
culture bottles (Nalgene, Rochester NY). Cultures were grown at 37°C with shaking for 11 
to 14 days, until reaching an OD of 1.0. Once at an OD of 1.0, 20 cultures were transferred 
to 15mL conical tubes and spun at 4000 RPM for 10 minutes at 4°C. Cultures were then 
resuspended in 250-500μL of 7H9/OADC/tween/glycerol and spotted onto 7H10/OADC/
tween/glycerol plates supplemented with 0.5, 2, or 5μg/mL rifampicin (Sigma, R3501), 
1μg/mL isoniazid (Sigma, I3377), or 5μg/mL ethambutol (MP Biomedicals, 157949). Once 
spread using sterile glass beads (4mm diameter), plates were allowed to dry and 
subsequently incubated at 37°C for 28 days. Cell counts were determined by serial dilution 
of 4 cultures for each strain. The drug resistance rate was determined by calculating m (the 
estimated number of mutations per culture) based on the number of mutants (r) observed on 
each plate using the Ma, Sarkar, Sandri (mss) method as previously described33,35. Dividing 
m by Nt, the number of cells plated for each culture, gives an estimated drug resistance rate. 
95% confidence intervals were estimated using equations (24) and (25) as described in 
Roshe and Foster33,36. For comparing pairs of fluctuation analysis data (Figure 2), the 
nonparametric two-sided Wilcoxon rank sum test (also known as the Mann-Whitney U-test) 
was performed using the ranksum command in Matlab with alpha set to 0.05, comparing the 
frequency of drug resistant mutants in each culture.
Fluctuation analysis data analysis
To estimate the extent to which the data met the assumptions of Luria-Delbrück fluctuation 
analysis, we performed a curve fitting analysis as described by Lang and Murray35. Briefly, 
data were fit using either a one-parameter model consistent with the Luria-Delbrück model, 
or a two-parameter model containing an additional parameter describing a Poisson 
distribution. The fit of each model was assessed using the least-squares methodology 
described by Lang and Murray, with AICC calculated as described previously39. A lower 
AICC reflects a better fit given a penalty for increasing the number of parameters, and a 
negative ΔAICC (ΔAICC = AICC (one-parameter) – AICC (two parameter)) indicates the one 
parameter model is a better approximation of the data.
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Determination of target size
The number of rpoB mutations conferring resistance to 0.5, 2, and 5μg/mL of rifampicin was 
determined by isolating 100 colonies, five from each fluctuation analysis culture, into 100μL 
Middlebrook 7H9 supplemented with 10% Middlebrook OADC, 0.0005% tween 80, and 
0.005% glycerol. Cultures were grown overnight at 37°C, and then heat-inactivated at 85°C 
for 2 hours. Heat-inactivated culture was then used as template for PCR and sequencing 
using primers previously described72. Sequences were analyzed for mutation relative to the 
reference sequence H37Rv, and totaled. For each culture, duplicate mutations were only 
counted once. The absolute number of unique mutations observed across cultures for a given 
condition was used to determine target size for each strain under each condition.
Estimate of mutation rate from human isolates
To determine the per base, per day mutation rate in human isolates, phylogenies were 
created using the concatenated SNP sequences reported by Gardy et al from a clonal 
outbreak of a Lineage 4 (Euro-American) strain in British Columbia, Canada42 using 
BEAST v.1.7.2 43,44 to perform Bayesian MCMC analysis. Prior to phylogenetic analysis, 
SNPs located in repeat regions (PE_PGRSs, PPEs, and transposable elements) were 
excluded, consistent with our previous experimentally validated analysis of SNPs from 
whole genome sequencing to estimate mutation rate6. Concatenated SNP sequences were 
compiled and prepared using BEAUti v1.7.2 to select analysis parameters and construct the 
xml input file. Concatenated sequences were converted to NEXUS format, and loaded into 
BEAUti where time was noted for each isolate. Time was defined in days based on time 
elapsed from symptom onset relative to isolation of the historical isolate, MT0005 (1995). A 
GTR substitution model was used with empirically determined base frequencies. Default 
priors were used for 10,000,000 chains. Output was analyzed in Tracer v1.5, and all 
parameters produced an effective sample size of 200 or greater. Phylogenetic tree 
construction was completed using TreeAnnotator v1.7.2 with a posterior probability limit of 
0.5 and a burnin of 1000 trees, leaving 9001 potential trees for construction. Tree 
visualization was completed using FigTree v1.3.1 and the tree was rooted on MT0005, with 
the most likely tree depicted in Supplementary Figure 1.
Mathematical simulation of drug resistance
We developed a compartmental, partially stochastic mathematical model of the evolution of 
drug resistance within an individual according to the following set of equations:
(1)
(2)
(3)
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(4)
Where:
(5)
(6)
(7)
(8)
Here, NS(t), NR(t), NH(t), NMDR(t) are the population sizes of the susceptible, rifampicin 
resistant, isoniazid resistant, and MDR populations at time (t), respectively. The parameters 
b and dA represent the birth and rates of bacteria in each population. The subscripted mX·Y 
parameters are the number of bacteria transitioning from population NY to population NX. m 
is a stochastically determined parameter, determined by a random Poisson variable where 
lambda is determined by the mutation rate to resistance times the population size of the 
susceptible population. These equations were parameterized with the values displayed in 
Supplementary Table 6. All simulations were run in Matlab (Natick, MA). For all 
simulations and for both mutation parameter sets (μH−W & μR−W, μH−CDC & μR−CDC), 
simulations of the evolution of drug resistance were run 100,000 times to determine the 
probability of observing drug resistance with a given set of parameters. To determine the 
effect of varying birthrate, 10 simulations of 200,000 simulated patients (100,000 per 
simulated strain) each were run with b = (0.20:1.10 in increments of 0.10), giving a net birth 
rate of 0.05:0.95. To determine the effect of varying the fitness of drug resistance mutants, 
10 simulations of 200,000 patients each (100,000 per simulated strain) were run with crH = 
crR = (0.0 : 0.90 in increments of 0.10). For all simulations, bacterial burden was allowed to 
increase to 1012 bacteria within a patient, and the probability of observing rifampicin 
resistance, isoniazid resistance, and MDR was determined by dividing the number of 
simulated patients with at least one resistant bacterium by the total number of simulated 
patients. To determine the probability of observing resistance in a model where mutation is 
determined by replication dynamics, we used equation 2 from Colijn et al (2011)47 with the 
parameters listed in Supplementary Figure 2c.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Lineage 2 strains more rapidly acquire rifampicin resistance
Fluctuation analysis was used to determine the rifampicin (2μg/mL) resistance rate of 
clinical and laboratory strains from both Lineage 2 and Lineage 4. Strains from Lineage 4 
are in red; strains from Lineage 2 are in blue. Circles represent mutation frequency (number 
of mutants per cell plated in a single culture), where darker circles represent multiple 
cultures with the same frequency. Bars represent the estimated mutation rate, with error bars 
representing the 95% confidence interval. Strains are displayed on the x-axis and the 
rifampicin resistance rate is displayed on the y-axis in log-scale. Values are listed in 
Supplementary Table 1.
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Figure 2. Altering drug concentration does not alter the observation that Lineage 2 strains more 
rapidly acquire rifampicin resistance
Fluctuation analysis was used to determine the rifampicin (0.5, 2, 5μg/mL) resistance 
mutation rate of representative strains from both Lineage 2 and Lineage 4 (HN878 and 
CDC1551, respectively). The Lineage 4 strain CDC1551 is in red, and the Lineage 2 strain 
HN878 is in blue. Circles represent mutation frequency (number of mutants per cell plated 
in a single culture), where darker circles represent multiple cultures with the same 
frequency. Bars represent the estimated mutation rate, with error bars representing the 95% 
confidence interval. Significance was determined by comparing strain pairs using the 
Wilcoxon rank-sum test. Strains are displayed on the x-axis and the rifampicin resistance 
rate is displayed on the y-axis in log-scale. Values are listed in Supplementary Table 1.
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Figure 3. The cumulative distribution of drug resistant mutants from both lineages indicates that 
mutations do not occur after exposure to antibiotic
(a) Curve fitting analysis was performed to determine if the cumulative distribution of the 
fluctuation analysis data from Lineage 4 strain CDC-1551 plated on rifampicin, 0.5μg/mL 
better fit a one-parameter Luria-Delbrück (LD) model, a one parameter Poisson model 
(Poiss), or a two-parameter Luria-Delbrück and Poisson mixture model (TP). The number of 
mutants per culture is displayed on the x-axis, and the probability of observing x or fewer 
mutants per culture is shown on the y-axis. (b) Fitting as in (a) for Lineage 2 strain HN878 
plated on rifampicin, 0.5μg/mL. (c) Fitting as in (a) for Lineage 4 strain CDC-1551 plated 
on rifampicin, 2μg/mL. (d) Fitting as in (a) for Lineage 2 strain HN878 plated on rifampicin, 
2μg/mL. (e) Fitting as in (a) data for Lineage 4 strain CDC-1551 plated on rifampicin, 
5μg/mL. (f) Fitting as in (a) data for Lineage 2 strain HN878 plated on rifampicin, 5μg/mL. 
(g) To determine which model best fit each data set, we determined the Akaike Information 
Criterion, corrected for small sample size (AICC). A smaller AICC represents a better fit, 
given a penalty for more parameters in a model. If the AICC(LD) is smaller than the 
AICC(TP), then the resulting value will be negative, reflecting a better fit for the LD model 
(see Supplementary Table 2).
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Figure 4. Small differences in target size and differences in basal mutation rate are responsible 
for the observed differences drug resistance rate
(a) The target size (the number of mutations conferring rifampicin resistance) of each strain 
under each condition was determined by sequencing the rifampicin resistance determining 
region of 100 isolates from each strain in each condition. Each mutation is shown on the x-
axis, with coordinates representing position within rpoB (Rv0667). The number of mutants 
per strain uniquely formed within a culture is shown on the y-axis. The Lineage 4 strain, 
CDC1551, is shown in red; the Lineage 2 strain is shown in blue. On the right, the target 
size - the number of unique mutations conferring rifampicin resistance – is shown. (b) The 
per base pair mutation rate is determined by normalizing the drug resistance rate by target 
size. Drug concentration is shown on the x-axis, mutation rate per base pair is shown on a 
linear scale on the y-axis. Lineage 4 is shown in red; Lineage 2 is shown in blue. 
Significance was determined by comparing strain pairs using the Wilcoxon rank-sum test; 
error bars represent 95% confidence intervals. Values are found in Supplementary Table 4.
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Figure 5. A representative Lineage 2 strain acquires isoniazid and ethambutol resistance at a 
higher rate
Fluctuation analysis was used to determine the isoniazid (1μg/mL) and ethambutol (5μg/mL) 
resistance rate for the Lineage 4 strain, CDC1551, (shown in red) and the Lineage 2 strain, 
HN878 (shown in blue). Circles represent mutation frequency (number of mutants per cell in 
a single culture), where darker circles represent multiple cultures with the same frequency. 
Bars represent the estimated mutation rate, with error bars representing the 95% confidence 
interval. Significance was determined by non-overlapping 95% confidence interval. Values 
are listed in Supplementary Table 1.
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Figure 6. Bayesian MCMC analysis reveals a mutation rate in humans similar to that estimated 
in strains from the macaque model and in vitro
(a) The number of SNPs and the number of days separating the clinical isolate and MT0005 
are plotted. SNPs located in repeat regions (PE_PGRSs, PPEs, and transposable elements) 
were excluded, consistent with our previous analysis6. The data are fit to a first order 
polynomial to illustrate the trend. (b) Estimates of mutation rate in human isolates were 
derived by reconstructing the phylogeny from the isolates represented in (a). Mutation rate is 
shown on the y-axis in log scale. Estimates of mutation rate from the macaque model and 
the infecting strain, Erdman (in vitro) were determined previously6. Error bars represent 
95% confidence intervals.
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Figure 7. A stochastic simulation mathematical model predicts the emergence of MDR-TB 
before the onset of treatment
(a) Estimates of the probability of observing MDR within a population were derived using a 
stochastic mathematical model of resistance in 200,000 simulations, 100,000 for each 
lineage. Model parameters are listed in Supplementary Table 6. Bacterial burden at 
diagnosis is shown on the x-axis, the probability of observing resistance is shown on the y-
axis in log scale. Estimates for Lineage 4 are shown in red, Lineage 2 in blue. (b, c) To 
determine the sensitivity of our model to variations in growth rate and fitness, we varied 
each parameter (see Supplementary Table 6) and determined the probability of observing 
resistance (z-axis, log scale) at any given bacterial burden (y-axis, log scale) for a specified 
parameter set (x-axis).
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